Is Novartis paying Vasella too much?

Former Novartis CEO Dan Vasella's 2009 bonus will be close to three times the amount he would be due based on relative earnings growth among large-cap peers, according to a new corporate-governance report. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.